Merck’s Winrevair Approved For PAH In Europe As Initial US Launch Progresses

Q1 Revenue Totaled $70m, 60% From Stocking

 
• By Mandy Jackson

Merck & Co. won European Commission approval for Winrevair on top of other medicines for pulmonary arterial hypertension and expects an initial EU launch in Germany.

PULMONARY HYPERTENSION Top view, Doctor writing medical records on a clipboard, medical equipment
Winrevair was approved in Europe for use on top of other PAH medicines • Source: Shutterstock

More from New Products

More from Scrip